Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 3
Submit an article Journal homepage
14,390
Views
164
CrossRef citations to date
0
Altmetric
Original research

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

Christian KleinRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandCorrespondence[email protected]
,
Inja WaldhauerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Valeria G. NicoliniRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Anne Freimoser-GrundschoberRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Tapan NayakRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Danielle J. VugtsRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
,
Claire DunnRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Marije BolijnRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
,
Jörg BenzRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Martine StihleRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Sabine LangRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Michaele RoemmeleRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Thomas HoferRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Erwin van PuijenbroekRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
David WittigRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandORCID Iconhttp://orcid.org/0000-0002-3296-6809
ORCID Icon,
Samuel MoserRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Oliver AstRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Peter BrünkerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Ingo H. GorrRoche Pharma Research & Early Development, Roche Innovation Center Munich, Penzberg, Germany
,
Sebastian NeumannRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Maria Cristina de Vera MudryRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, SwitzerlandORCID Iconhttp://orcid.org/0000-0003-1016-7480
ORCID Icon,
Heather HintonRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Flavio CrameriRoche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
,
Jose SaroRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandORCID Iconhttp://orcid.org/0000-0003-0778-3864
ORCID Icon,
Stefan EversRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandORCID Iconhttp://orcid.org/0000-0001-9587-5325
ORCID Icon,
Christian GerdesRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Marina BacacRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Guus van DongenRoche Pharma Research & Early Development, Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
,
Ekkehard MoessnerRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
&
Pablo UmañaRoche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, SwitzerlandCorrespondence[email protected]
 show all
Article: e1277306 | Received 26 Oct 2016, Accepted 21 Dec 2016, Published online: 21 Feb 2017

Citations (164)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (18)

Vedran Vasic, Can Buldun, Manfred Ritz, Steffen Dickopf, Guy J. Georges, Christian Spick, Alessa Peuker, Thomas Meier, Klaus Mayer & Ulrich Brinkmann. (2023) Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy. mAbs 15:1.
Read now
Britta Lipinski, Laura Unmuth, Paul Arras, Stefan Becker, Christina Bauer, Lars Toleikis, Simon Krah, Achim Doerner, Desislava Yanakieva, Ammelie Svea Boje, Katja Klausz, Matthias Peipp, Vanessa Siegmund, Andreas Evers, Harald Kolmar, Lukas Pekar & Stefan Zielonka. (2023) Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. mAbs 15:1.
Read now
Louis Plüss, Frederik Peissert, Abdullah Elsayed, Giulia Rotta, Jonas Römer, Sheila Dakhel Plaza, Alessandra Villa, Emanuele Puca, Roberto De Luca, Annette Oxenius & Dario Neri. (2023) Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen. mAbs 15:1.
Read now
Margaret Bohmer, Yonger Xue, Katarina Jankovic & Yizhou Dong. (2023) Advances in engineering and delivery strategies for cytokine immunotherapy. Expert Opinion on Drug Delivery 20:5, pages 579-595.
Read now
Jerome Egli, Stefan Heiler, Felix Weber, Guido Steiner, Timo Schwandt, Katharine Bray-French, Christian Klein, Sebastian Fenn, Gregor P. Lotz, Eugenia Opolka-Hoffmann, Thomas E. Kraft, Laetitia Petersen, Rebecca Moser, Jonathan DeGeer, Michel Siegel, Daniela Finke, Juliana Bessa & Antonio Iglesias. (2022) Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice. mAbs 14:1.
Read now
J.-Y. Lee, K. Lee & B. Koh. (2021) Identification of new IL-7Rα small-molecule agonists: a multi-computational approach. SAR and QSAR in Environmental Research 32:9, pages 719-729.
Read now
Seung E. Cha, Maciej Kujawski, Paul J. Yazaki, Christine Brown & John E. Shively. (2021) Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. OncoImmunology 10:1.
Read now
Inja Waldhauer, Valeria Gonzalez-Nicolini, Anne Freimoser-Grundschober, Tapan K Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, Edwin J. W. Geven, Johannes Sam, Sabine Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin Van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep K. Garg, Gregory Dugan, Federica Cavallo, Gonzalo Acuna, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña & Christian Klein. (2021) Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. mAbs 13:1.
Read now
Laura Amanda Boos, Isla Leslie & James Larkin. (2020) Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs 29:7, pages 739-753.
Read now
Ana Victoria Casadesús, Claire Deligne, Béré Kadjdiatou Diallo, Katya Sosa, Nathalie Josseaume, Circe Mesa, Kalet León, Tays Hernández & Jean-Luc Teillaud. (2020) A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy. OncoImmunology 9:1.
Read now
Maciej Kujawski, Mark Sherman, Susanta Hui, Darren Zuro, Wen-Hui Lee, Paul Yazaki, Anakim Sherman, Barbara Szpikowska, Junie Chea, Desiree Lasiewski, Kofi Poku, Harry Li, David Colcher, Jeffrey Wong & John E. Shively. (2020) Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation. OncoImmunology 9:1.
Read now
Jun-Young Lee, Eunjin Lee, Sung-Wook Hong, Daeun Kim, O. Eunju, Jonathan Sprent, Sin-Hyeog Im, You Jeong Lee & Charles D. Surh. (2020) TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. OncoImmunology 9:1.
Read now
Patrizia Murer, Louis Plüss & Dario Neri. (2020) A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis. mAbs 12:1.
Read now
Sadia Sikder, Vrinda Gote, Meshal Alshamrani, Jeff Sicotte & Dhananjay Pal. (2019) Long-term delivery of protein and peptide therapeutics for cancer therapies. Expert Opinion on Drug Delivery 16:10, pages 1113-1131.
Read now
Zhuo Mao, Xuegang Fu, Zeyun Dong, Xiaodong Jian, Jian Sun & Jing Wei. (2018) Study of the molecular mechanism of interleukin-2 mutein D10 binding to IL-2 receptors by molecular simulations. Molecular Simulation 44:12, pages 973-980.
Read now
Keunok Jung, Ji-Hee Ha, Jung-Eun Kim, Jeong-Ah Kim, Ye-Jin Kim, Chul-Ho Kim & Yong-Sung Kim. (2018) Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells. OncoImmunology 7:7.
Read now
Camille Martin, Claire Kizlik-Masson, André Pèlegrin, Hervé Watier, Marie-Claude Viaud-Massuard & Nicolas Joubert. (2018) Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France. mAbs 10:2, pages 210-221.
Read now
Christian Klein, Marina Bacac, Pablo Umana & Günter Fingerle-Rowson. (2017) Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs 26:10, pages 1145-1162.
Read now

Articles from other publishers (146)

Noor Momin. (2023) Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapies. Current Opinion in Biotechnology 84, pages 102994.
Crossref
Ahmad Alzamami. (2023) Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy. Medical Oncology 40:12.
Crossref
D. C. A. Quixabeira, S. Pakola, E. Jirovec, R. Havunen, S. Basnet, J. M. Santos, T. V. Kudling, J. H. A. Clubb, L. Haybout, V. Arias, S. Grönberg-Vähä-Koskela, V. Cervera-Carrascon, E. Kerkelä, A. Pasanen, M. Anttila, J. Tapper, A. Kanerva & A. Hemminki. (2023) Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Cancer Gene Therapy.
Crossref
Markus Joerger, Emiliano Calvo, Heinz Laubli, Juanita Lopez, Guzmán Alonso, Elena Corral de la Fuente, Dagmar Hess, David König, Vicky Sanchez Perez, Christoph Bucher, Sangeeta Jethwa & Elena Garralda. (2023) Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for ImmunoTherapy of Cancer 11:11, pages e007784.
Crossref
Aliyah B. Silver, Stephany Y. Tzeng, Mallory Lager, Jeremy Wang, Jun Ishihara, Jordan J. Green & Jamie B. Spangler. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell Reports Medicine 4:11, pages 101289.
Crossref
Leonardo Trujillo-Cirilo, Benny Weiss-Steider, Carlos Adrian Vargas-Angeles, Maria Teresa Corona-Ortega & Rosalva Rangel-Corona. (2023) Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion. Cytokine 170, pages 156334.
Crossref
Lindsay Williams, Lin Li, Paul J. Yazaki, Patty Wong, Aaron Miller, Teresa Hong, Erasmus K. Poku, Supriyo Bhattacharya, John E. Shively & Maciej Kujawski. (2023) Generation of IL‐2‐Fc‐antibody conjugates by click chemistry. Biotechnology Journal 18:9.
Crossref
Weiwei Wu, Tiongsun Chia, Jia Lu, Xue Li, Jian Guan, Yaning Li, Fenggen Fu, Shuaixiang Zhou, Ye Feng, Junjie Deng, Jia Zou, Jiya Sun, Ying Yao, Xiaomin Ling, Zhihai Wu, Ying Zhang, Jinling Xu, Feifei Wang, Xue Liang, Min Wu, Huisi Liu, Bingliang Chen & Kaijie He. (2023) IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nature Cancer.
Crossref
Amanda L. Gill, Peter H. Wang, Judong Lee, William H. Hudson, Satomi AndoKoichi Araki, Yinghong HuAndreas Wieland, Sejin Im, Autumn GavoraChristopher B. Medina, Gordon J. Freeman, Masao Hashimoto, Steven L. Reiner & Rafi Ahmed. (2023) PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Science Immunology 8:86.
Crossref
Warren J. Leonard & Jian-Xin Lin. (2023) Strategies to therapeutically modulate cytokine action. Nature Reviews Drug Discovery.
Crossref
Jacob Gadwa, Maria Amann, Thomas E. Bickett, Michael W. Knitz, Laurel B. Darragh, Miles Piper, Benjamin Van Court, Sanjana Bukkapatnam, Tiffany T. Pham, Xiao-Jing Wang, Anthony J. Saviola, Laura Codarri Deak, Pablo Umaña, Christian Klein, Angelo D’Alessandro & Sana D. Karam. (2023) Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Reports Medicine 4:8, pages 101150.
Crossref
Yong Fu, Renhong Tang & Xiaofeng Zhao. (2023) Engineering cytokines for cancer immunotherapy: a systematic review. Frontiers in Immunology 14.
Crossref
Christopher J. Nirschl, Heather R. Brodkin, Celesztina Domonkos, Connor J. Dwyer, Daniel J. Hicklin, Nesreen Ismail, Cynthia Seidel-Dugan, Philipp Steiner, Zoe Steuert, Jenna M. Sullivan, William M. Winston & Andres Salmeron. (2023) mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity. Cancer Immunology Research 11:7, pages 962-977.
Crossref
Dan Lu, Rajbharan Yadav, Patrick Holder, Eugene Chiang, Shomyseh Sanjabi, Victor Poon, Matthew Bernett, Rajat Varma, Ke Liu, Irene Leung, Liz Bogaert, John Desjarlais, Vittal Shivva, Iraj Hosseini & Saroja Ramanujan. (2023) Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics. European Journal of Pharmaceutical Sciences 186, pages 106450.
Crossref
Miro E. Raeber, Dilara Sahin, Ufuk Karakus & Onur Boyman. (2023) A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. eBioMedicine 90, pages 104539.
Crossref
Christoph Jindra, Edmund K. Hainisch & Sabine Brandt. (2023) Immunotherapy of Equine Sarcoids—From Early Approaches to Innovative Vaccines. Vaccines 11:4, pages 769.
Crossref
Yangyihua Zhou, Guiqi Quan, Yujun Liu, Ning Shi, Yahui Wu, Ran Zhang, Xiang Gao & Longlong Luo. (2023) The application of Interleukin-2 family cytokines in tumor immunotherapy research. Frontiers in Immunology 14.
Crossref
Theint Aung, William S. Grubbe, Rebecca J. Nusbaum & Juan L. Mendoza. (2023) Recent and future perspectives on engineering interferons and other cytokines as therapeutics. Trends in Biochemical Sciences 48:3, pages 259-273.
Crossref
Vladislav S. Rybchenko, Teimur K. Aliev, Anna A. Panina, Mikhail P. Kirpichnikov & Dmitry A. Dolgikh. (2023) Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects. Pharmaceutics 15:2, pages 336.
Crossref
Huan Zhang, Simiao Wang, Man Sun, Yaxin Cui, Jianming Xing, Lesheng Teng, Zhifang Xi & Zhaogang Yang. (2023) Exosomes as smart drug delivery vehicles for cancer immunotherapy. Frontiers in Immunology 13.
Crossref
Mélanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Annamaria Kauzlaric, Krisztian Homicsko, Laura Codarri Deak, Pablo Umaña, Christian Klein & Douglas Hanahan. (2023) Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages. Immunity 56:1, pages 162-179.e6.
Crossref
Asma Mousavi, Faeze Gharibpoor, Sepideh Razi & Nima Rezaei. 2023.
Ana Victoria Casadesús, Beatriz María Cruz, Wilden Díaz, Miguel Ángel González, Tania Gómez, Briandy Fernández, Addys González, Nuris Ledón, Katya Sosa, Kathleen Castro, Armando López, Claudia Plasencia, Yaima Ramírez, Jean-Luc Teillaud, Calixto Hernández, Kalet León & Tays Hernández. (2022) Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy. Frontiers in Immunology 13.
Crossref
Samuel L. Crine & K. Ravi Acharya. (2021) Molecular basis of C‐mannosylation – a structural perspective. The FEBS Journal 289:24, pages 7670-7687.
Crossref
Ahmed L. Alaofi. (2022) IL-2 Flexible Loops Might Play a Role in IL-2 Interaction with the High-Affinity IL-2 Receptor: A Molecular Dynamics (MD) Study. Journal of Chemistry 2022, pages 1-7.
Crossref
K. M. Konoplina, E. N. Kosobokova & V. S. Kosorukov. (2022) Current approaches to assessing the biological activity of immunocytokines <i>in vitro</i>. Russian Journal of Biotherapy 21:3, pages 10-22.
Crossref
Masao Hashimoto, Koichi Araki, Maria A. Cardenas, Peng Li, Rohit R. Jadhav, Haydn T. Kissick, William H. Hudson, Donald J. McGuire, Rebecca C. Obeng, Andreas Wieland, Judong Lee, Daniel T. McManus, James L. Ross, Se Jin Im, Junghwa Lee, Jian-Xin Lin, Bin Hu, Erin E. West, Christopher D. Scharer, Gordon J. Freeman, Arlene H. Sharpe, Suresh S. Ramalingam, Alex Pellerin, Volker Teichgräber, William J. Greenleaf, Christian Klein, Jorg J. Goronzy, Pablo Umaña, Warren J. Leonard, Kendall A. Smith & Rafi Ahmed. (2022) PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610:7930, pages 173-181.
Crossref
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C. Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yanguez, Tamara Hüsser, Ramona Schlenker, Marisa Mariani, Vinko Tosevski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Gueripel, Stephan Wullschleger, Melanie Tichet, Douglas Hanahan, Haydn T. Kissick, Stephane Leclair, Anne Freimoser-Grundschober, Stefan Seeber, Volker Teichgräber, Rafi Ahmed, Christian Klein & Pablo Umaña. (2022) PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature 610:7930, pages 161-172.
Crossref
Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse & Holger N. Lode. (2022) The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers 14:19, pages 4842.
Crossref
Olivier Demaria, Laurent Gauthier, Marie Vetizou, Audrey Blanchard Alvarez, Constance Vagne, Guillaume Habif, Luciana Batista, William Baron, Nourhène Belaïd, Mathilde Girard-Madoux, Cedric Cesari, Melody Caratini, Frédéric Bosco, Olivier Benac, Julie Lopez, Aurore Fenis, Justine Galluso, Sylvia Trichard, Barbara Carrette, Florent Carrette, Aurélie Maguer, Solène Jaubert, Audrey Sansaloni, Robin Letay-Drouet, Camille Kosthowa, Naouel Lovera, Arnaud Dujardin, Fabien Chanuc, Mélanie Le Van, Sivan Bokobza, Nicolas Jarmuzynski, Camille Fos, Nicolas Gourdin, Romain Remark, Eric Lechevallier, Nicolas Fakhry, Sébastien Salas, Jean-Laurent Deville, Roger Le Grand, Cécile Bonnafous, Lukas Vollmy, Agnès Represa, Sabrina Carpentier, Benjamin Rossi, Ariane Morel, Stéphanie Cornen, Ivan Perrot, Yannis Morel & Eric Vivier. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Reports Medicine 3:10, pages 100783.
Crossref
Dongfu Jin, Yaxin Jiang, Lu Chang, Jing Wei & Jian Sun. (2022) New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. International Immunopharmacology 110, pages 108935.
Crossref
Dasom Kim, Jin-Ho Park, Tae-Yoon Kim, Dong-Gun Kim, June-Ho Byun & Hak-Sung Kim. (2022) Enhanced half-life and antitumor activity of interleukin-15 through genetic fusion of a serum albumin-specific protein binder. International Journal of Pharmaceutics 625, pages 122059.
Crossref
Joel R. Eisner, Kirk D. Beebe, Gregory M. Mayhew, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jill Mooney, Michael V. Milburn, David Foureau, Richard L. White, Asim Amin & Marcos E. Milla. (2022) Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications 2:8, pages 894-903.
Crossref
Tania Carmenate, Galia Montalvo, Sum Lai Lozada, Yaretnis Rodriguez, Yaquelin Ortiz, Claudia Díaz, Janet Avellanet, Juhee Kim, Charles D. Surh, Luis Graça & Kalet León. (2022) The antitumor effect induced by an IL-2 ‘no-alpha’ mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance. Frontiers in Immunology 13.
Crossref
Seyed Amir Sanatkar, Arash Heidari & Nima Rezaei. (2022) Cancer Immunotherapy: Diverse Approaches and Obstacles. Current Pharmaceutical Design 28:29, pages 2387-2403.
Crossref
David B Rosen, Anne Månsson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Enping Hong, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zúñiga, Kathy Bang, Simran Singh Sabharwal, Karan Uppal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Diana Reich, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M Singel, Kennett Sprogøe & Juha Punnonen. (2022) TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer. Journal for ImmunoTherapy of Cancer 10:7, pages e004991.
Crossref
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens & Lorenzo Galluzzi. (2022) Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery 21:6, pages 440-462.
Crossref
Hermann J. Hütte, Birgit Tiemann, Aleksandra Shcherbakova, Valerian Grote, Marcus Hoffmann, Lorenzo Povolo, Mark Lommel, Sabine Strahl, Sergey Y. Vakhrushev, Erdmann Rapp, Falk F. R. Buettner, Adnan Halim, Anne Imberty & Hans Bakker. (2022) A Bacterial Mannose Binding Lectin as a Tool for the Enrichment of C- and O-Mannosylated Peptides. Analytical Chemistry 94:20, pages 7329-7338.
Crossref
Christopher J. Nirschl, Heather R. Brodkin, Daniel J. Hicklin, Nesreen Ismail, Kristin Morris, Cynthia Seidel-Dugan, Philipp Steiner, Zoe Steuert, Jenna M. Sullivan, Ethika Tyagi, William M. Winston & Andres Salmeron. (2022) Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression. Cancer Immunology Research 10:5, pages 581-596.
Crossref
Suheil Albert Atallah-Yunes & Michael J. Robertson. (2022) Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Frontiers in Immunology 13.
Crossref
Jhalak Dholakia, Alexander C. Cohen, Charles A. LeathIIIIII, Elizabeth T. Evans, Ronald D. Alvarez & Premal H. Thaker. (2022) Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications. Current Oncology Reports 24:4, pages 389-397.
Crossref
Byeongjun Yu, Dohyun Yoo, Ki Hyun Kim, Tae Woo Kim, Seho Park, Yujin Kim, Youngju Son, Jinjoo Kim, Ilkoo Noh, Chang‐Hee Whang, Junho Chung & Sangyong Jon. (2022) Effective Combination Immunotherapy through Vessel Normalization Using a Cancer‐Targeting Antiangiogenic Peptide–Antibody Hybrid. Advanced Therapeutics 5:4.
Crossref
Tabassom Mohajershojai, Preeti Jha, Anna Boström, Fredrik Y. Frejd, Paul J. Yazaki & Marika Nestor. (2022) In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer. Frontiers in Oncology 12.
Crossref
Zhenhua Ren, Anli Zhang, Zhichen Sun, Yong Liang, Jianfeng Ye, Jian Qiao, Bo Li & Yang-Xin Fu. (2022) Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation 132:3.
Crossref
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao & Zhigang Tian. (2022) The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cellular & Molecular Immunology 19:2, pages 192-209.
Crossref
Jun Kim, Seounghun Kang, Kyoung Won Kim, Myeong-Gang Heo, Dae-In Park, Joon-Hyung Lee, Nam Ju Lim, Dal-Hee Min & Cheolhee Won. (2022) Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy. Biomaterials 280, pages 121257.
Crossref
Áron Roxin & François Bénard. 2022. Nuclear Medicine and Immunology. Nuclear Medicine and Immunology 61 101 .
Adrián Gironda-Martínez, Émile M. D. Gorre, Luca Prati, Jean-François Gosalbes, Sheila Dakhel, Samuele Cazzamalli, Florent Samain, Etienne J. Donckele & Dario Neri. (2021) Identification and Validation of New Interleukin-2 Ligands Using DNA-Encoded Libraries. Journal of Medicinal Chemistry 64:23, pages 17496-17510.
Crossref
Antonios G. A. Kolios, George C. Tsokos & David Klatzmann. (2021) Interleukin-2 and regulatory T cells in rheumatic diseases. Nature Reviews Rheumatology 17:12, pages 749-766.
Crossref
Aliyah B. Silver, Elissa K. Leonard, Joseph R. Gould & Jamie B. Spangler. (2021) Engineered antibody fusion proteins for targeted disease therapy. Trends in Pharmacological Sciences 42:12, pages 1064-1081.
Crossref
Yue Du & Jian Xu. (2021) Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials 33:48.
Crossref
Maki Kobayashi, Katsuhiko Kojima, Kazutaka Murayama, Yuji Amano, Takashi Koyama, Naoko Ogama, Toshikazu Takeshita, Tatsuro Fukuhara & Nobuyuki Tanaka. (2021) MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance. Cancer Science 112:11, pages 4478-4489.
Crossref
Yuanming Xu, Lucia Campos Carrascosa, Yik Andy Yeung, Matthew Ling-Hon Chu, Wenjing Yang, Ivana Djuretic, Danielle C. Pappas, John Zeytounian, Zhouhong Ge, Valeska de Ruiter, Gabriel R. Starbeck-Miller, James Patterson, Diamanda Rigas, Shih-Hsun Chen, Eugenia Kraynov, Patrick P. Boor, Lisanne Noordam, Michael Doukas, Dave Tsao, Jan N. Ijzermans, Jie Guo, Dirk J. Grünhagen, Joris Erdmann, Joanne Verheij, Martin E. van Royen, Pascal G. Doornebosch, Renny Feldman, Terrence Park, Salah Mahmoudi, Magdalena Dorywalska, Irene Ni, Sherman M. Chin, Tina Mistry, Lidia Mosyak, Laura Lin, Keith A. Ching, Kevin C. Lindquist, Changhua Ji, Luz Marina Londono, Bing Kuang, Robert Rickert, Jaap Kwekkeboom, Dave Sprengers, Tzu-Hsuan Huang & Javier Chaparro-Riggers. (2021) An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. Cancer Immunology Research 9:10, pages 1141-1157.
Crossref
Golnaz Morad, Beth A. Helmink, Padmanee Sharma & Jennifer A. Wargo. (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184:21, pages 5309-5337.
Crossref
Clémence Riffard & Jean-Luc Teillaud. (2021) Les anticorps bispécifiques : une vieille histoire pleine d’avenir… avec les CAR-T !. Bulletin du Cancer 108:10, pages S168-S180.
Crossref
Stefanie Lesch & Saar Gill. (2021) The promise and perils of immunotherapy. Blood Advances 5:18, pages 3709-3725.
Crossref
Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li & Chong-xian Pan. (2021) Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology & Oncology 14:1.
Crossref
Ignacio Melero, Eduardo Castanon, Maite Alvarez, Stephane Champiat & Aurelien Marabelle. (2021) Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nature Reviews Clinical Oncology 18:9, pages 558-576.
Crossref
Amanda Nash, Samira Aghlara-Fotovat, Andrea Hernandez, Christopher Scull & Omid Veiseh. (2021) Clinical translation of immunomodulatory therapeutics. Advanced Drug Delivery Reviews 176, pages 113896.
Crossref
Shiho Minakata, Shino Manabe, Yoko Inai, Midori Ikezaki, Kazuchika Nishitsuji, Yukishige Ito & Yoshito Ihara. (2021) Protein C-Mannosylation and C-Mannosyl Tryptophan in Chemical Biology and Medicine. Molecules 26:17, pages 5258.
Crossref
Tomoyoshi Inoue, Thomas Byrne, Mitsuko Inoue, Madeline E. Tait, Patrick Wall, Annabel Wang, Michael R. Dermyer, Hanane Laklai, Joseph J. Binder, Clare Lees, Robert Hollingsworth, Liliana Maruri-Avidal, David H. Kirn & Donald M. McDonald. (2021) Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing. Molecular Cancer Therapeutics 20:8, pages 1481-1494.
Crossref
Aslan Mansurov, Abigail Lauterbach, Erica Budina, Aaron T. Alpar, Jeffrey A. Hubbell & Jun Ishihara. (2021) Immunoengineering approaches for cytokine therapy. American Journal of Physiology-Cell Physiology 321:2, pages C369-C383.
Crossref
Ivan S. Pires, Paula T. Hammond & Darrell J. Irvine. (2021) Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress. Advanced Therapeutics 4:8.
Crossref
Seung Mo Jin, Sang Nam Lee, Yeon Jeong Yoo & Yong Taik Lim. (2021) Molecular and Macroscopic Therapeutic Systems for Cytokine‐Based Cancer Immunotherapy. Advanced Therapeutics 4:8.
Crossref
Biaggio Uricoli, Lacey A. Birnbaum, Priscilla Do, James M. Kelvin, Juhi Jain, Emma Costanza, Andrew Chyong, Christopher C. Porter, Sarwish Rafiq & Erik C. Dreaden. (2021) Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy. Advanced Healthcare Materials 10:15.
Crossref
Katharine Bray-French, Katharina Hartman, Guido Steiner, Céline Marban-Doran, Juliana Bessa, Neil Campbell, Meret Martin-Facklam, Kay-Gunnar Stubenrauch, Corinne Solier, Thomas Singer & Axel Ducret. (2021) Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside. Journal of Pharmaceutical Sciences 110:7, pages 2575-2584.
Crossref
Salah-Eddine Bentebibel & Adi Diab. (2021) Cytokines in the Treatment of Melanoma. Current Oncology Reports 23:7.
Crossref
Megan Mulholland, Gabriel Jakobsson, Yu Lei, Lena Sundius, Irena Ljungcrantz, Sara Rattik, Uwe J.F. Tietge & Daniel Engelbertsen. (2021) IL-2Rβγ signalling in lymphocytes promotes systemic inflammation and reduces plasma cholesterol in atherosclerotic mice. Atherosclerosis 326, pages 1-10.
Crossref
Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin, Harish Medlari Basappa, Sharon Hartstein, Ghenima Ahmil, Nicole S. Allen, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau, Karen Chang, Maria-Cristina Cuturi, Laura M. Davison, Dennis M. Ho, Suhasini Iyer, Udaya S. Rangaswamy, Preethi Sankaran, Ute Schellenberger, Roland Buelow & Nathan D. Trinklein. (2021) A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Scientific Reports 11:1.
Crossref
Dafne C. A. Quixabeira, Sadia Zafar, Joao M. Santos, Victor Cervera-Carrascon, Riikka Havunen, Tatiana V. Kudling, Saru Basnet, Marjukka Anttila, Anna Kanerva & Akseli Hemminki. (2021) Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in Immunology 12.
Crossref
Eric J. Hsu, Xuezhi Cao, Benjamin Moon, Joonbeom Bae, Zhichen Sun, Zhida Liu & Yang-Xin Fu. (2021) A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nature Communications 12:1.
Crossref
Isabella Lurje, Wiebke Werner, Raphael Mohr, Christoph Roderburg, Frank Tacke & Linda Hammerich. (2021) In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology 12.
Crossref
Aner Ottolenghi, Priyanka Bolel, Rhitajit Sarkar, Yariv Greenshpan, Muhammed Iraqi, Susmita Ghosh, Baisali Bhattacharya, Zoe V. Taylor, Kiran Kundu, Olga Radinsky, Roi Gazit, David Stepensky, Ron N. Apte, Elena Voronov & Angel Porgador. (2021) Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. Scientific Reports 11:1.
Crossref
Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis & Sophie Papa. (2021) Utilizing Immunocytokines for Cancer Therapy. Antibodies 10:1, pages 10.
Crossref
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2021) Immunomodulation by targeted anticancer agents. Cancer Cell 39:3, pages 310-345.
Crossref
Willem W. OverwijkMary A. TagliaferriJonathan Zalevsky. (2021) Engineering IL-2 to Give New Life to T Cell Immunotherapy. Annual Review of Medicine 72:1, pages 281-311.
Crossref
Yazhen Zhu, Qin Zhang, Chengjiang Wei, Ying Hu, Han Gong, Yi Liu, Hao Lai, Yan Feng & Yuan Lin. (2021) High-Precision Quantitative Analysis Reveals Carcinoembryonic Protein Expression Differs Among Colorectal Cancer Primary Foci and Metastases to Different Sites. Technology in Cancer Research & Treatment 20, pages 153303382110371.
Crossref
Rosa Nguyen & Wayne L. Furman. 2021. Successes and Challenges of NK Immunotherapy. Successes and Challenges of NK Immunotherapy 405 437 .
Dilara Sahin, Natalia Arenas-Ramirez, Matthias Rath, Ufuk Karakus, Monika Hümbelin, Merel van Gogh, Lubor Borsig & Onur Boyman. (2020) An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nature Communications 11:1.
Crossref
Ivan Y. Filin, Valeriya V. Solovyeva, Kristina V. Kitaeva, Catrin S. Rutland & Albert A. Rizvanov. (2020) Current Trends in Cancer Immunotherapy. Biomedicines 8:12, pages 621.
Crossref
Michael R. Mortensen, Jacqueline Mock, Marco Bertolini, Marco Stringhini, Marco Catalano & Dario Neri. (2020) Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. Oncotarget 11:44, pages 3972-3983.
Crossref
Tiziano Ongaro, Baptiste Gouyou, Marco Stringhini, Riccardo Corbellari, Dario Neri & Alessandra Villa. (2020) A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo . Oncotarget 11:41, pages 3698-3711.
Crossref
Baptiste Gouyou, Jacopo Millul, Alessandra Villa, Samuele Cazzamalli, Dario Neri & Mattia Matasci. (2020) Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide–Cytokine Conjugate. ACS Omega 5:40, pages 26077-26083.
Crossref
Guido Steiner, Céline Marban-Doran, Jessica Langer, Tatiana Pimenova, Gonzalo Duran-Pacheco, Denise Sauter, Anja Langenkamp, Corinne Solier, Thomas Singer, Katharine Bray-French & Axel Ducret. (2020) Enabling Routine MHC-II-Associated Peptide Proteomics for Risk Assessment of Drug-Induced Immunogenicity. Journal of Proteome Research 19:9, pages 3792-3806.
Crossref
John A. Hangasky, Thomas A. Waldmann & Daniel V. Santi. (2020) Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink. Frontiers in Immunology 11.
Crossref
Martin Frank, Daniela Beccati, Bas R. Leeflang & Johannes F.G. Vliegenthart. (2020) C-Mannosylation Enhances the Structural Stability of Human RNase 2. iScience 23:8, pages 101371.
Crossref
Romy Mueller, Sayeda Yasmin-Karim, Kaylie DeCosmo, Ana Vazquez-Pagan, Srinivas Sridhar, David Kozono, Juergen Hesser & Wilfred Ngwa. (2020) Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy. Physica Medica 76, pages 236-242.
Crossref
Alfredo Quijano-Rubio, Umut Y. Ulge, Carl D. Walkey & Daniel-Adriano Silva. (2020) The advent of de novo proteins for cancer immunotherapy. Current Opinion in Chemical Biology 56, pages 119-128.
Crossref
Shanling Shen, Gail Sckisel, Anupama Sahoo, Almin Lalani, Doug Den Otter, Josh Pearson, Jason DeVoss, Jay Cheng, Stephanie C. Casey, Ryan Case, Melissa Yang, Ray Low, Mark Daris, Bin Fan, Neeraj J. Agrawal & Khaled Ali. (2020) Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity. Frontiers in Immunology 11.
Crossref
Daniel R Lu, Hao Wu, Ian Driver, Sarah Ingersoll, Sue Sohn, Songli Wang, Chi-Ming Li & Hyewon Phee. (2020) Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein. Life Science Alliance 3:5, pages e201900520.
Crossref
Emanuele Puca, Philipp Probst, Marco Stringhini, Patrizia Murer, Giovanni Pellegrini, Samuele Cazzamalli, Cornelia Hutmacher, Baptiste Gouyou, Sarah Wulhfard, Mattia Matasci, Alessandra Villa & Dario Neri. (2019) The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors . International Journal of Cancer 146:9, pages 2518-2530.
Crossref
Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, Gang Huang, Quan-Yong Luo & Weibo Cai. (2020) ImmunoPET: Concept, Design, and Applications. Chemical Reviews 120:8, pages 3787-3851.
Crossref
O. Michalak, P. Krzeczyński, M. Cieślak, P. Cmoch, M. Cybulski, K. Królewska-Golińska, J. Kaźmierczak-Barańska, B. Trzaskowski & K. Ostrowska. (2020) Synthesis and anti–tumour, immunomodulating activity of diosgenin and tigogenin conjugates. The Journal of Steroid Biochemistry and Molecular Biology 198, pages 105573.
Crossref
Barbara Żyżyńska-Granica, Bartosz Trzaskowski, Małgorzata Dutkiewicz, Oliwia Zegrocka-Stendel, Maja Machcińska, Katarzyna Bocian, Magdalena Kowalewska & Katarzyna Koziak. (2020) The anti-inflammatory potential of cefazolin as common gamma chain cytokine inhibitor. Scientific Reports 10:1.
Crossref
Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi & Doriana Fruci. (2020) Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors. Frontiers in Immunology 10.
Crossref
Jonathan G. Pol, Pamela Caudana, Juliette Paillet, Eliane Piaggio & Guido Kroemer. (2020) Effects of interleukin-2 in immunostimulation and immunosuppression. Journal of Experimental Medicine 217:1.
Crossref
Emanuele Puca, Roberto De Luca, Frauke Seehusen, Josep Maria Monné Rodriguez & Dario Neri. (2020) Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice. Journal of Controlled Release 317, pages 282-290.
Crossref
Liming Liu, Raymond Evers & Diana Montgomery. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters 387 416 .
Minyu Wang, Sen Wang, Jayesh Desai, Joseph A Trapani & Paul J Neeson. (2020) Therapeutic strategies to remodel immunologically cold tumors. Clinical & Translational Immunology 9:12.
Crossref
Christine Ménétrier-Caux, Isabelle Ray-Coquard, Jean-Yves Blay & Christophe Caux. (2019) Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Hua Jing, Michael Hettich, Simone Gaedicke, Elke Firat, Mark Bartholomä & Gabriele Niedermann. (2019) Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Alicia Contet, Véronique Caussanel, Alain Beck & Peter Lowe. (2020) Immunotoxines et immunocytokines. médecine/sciences 35:12, pages 1054-1061.
Crossref
Yang Du, Yafei Qi, Zhengyu Jin & Jie Tian. (2019) Noninvasive imaging in cancer immunotherapy: The way to precision medicine. Cancer Letters 466, pages 13-22.
Crossref
Roberto De Luca, Baptiste Gouyou, Tiziano Ongaro, Alessandra Villa, Barbara Ziffels, Alessandro Sannino, Gianluca Buttinoni, Simone Galeazzi, Mirko Mazzacuva & Dario Neri. (2019) A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas. Frontiers in Oncology 9.
Crossref
Shiming Ye, Diane Cohen, Nicole A. Belmar, Donghee Choi, Siu Sze Tan, Mien Sho, Yoshiko Akamatsu, Han Kim, Ramesh Iyer, Jean Cabel, Marc Lake, Danying Song, John Harlan, Catherine Zhang, Yuni Fang, Alan F. Wahl, Patricia Culp, Diane Hollenbaugh & Debra T. Chao. (2019) A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity. Cancer Immunology Research 7:11, pages 1864-1875.
Crossref
Juha Punnonen, David Rosen, Luis Zuniga, Kennett Sprogøe & Mohammad Tabrizi. (2019) Cytokine Therapeutics in Cancer Immunotherapy: Design and Development. Current Pharmacology Reports 5:5, pages 377-390.
Crossref
Urmi Roy. (2019) Structure and Function of an Inflammatory Cytokine, Interleukin-2, Analyzed Using the Bioinformatic Approach. The Protein Journal 38:5, pages 525-536.
Crossref
Tien‐Hua Chen, Peter M. ‐H. Chang & Muh‐Hwa Yang. (2019) Novel immune‐modulating drugs for advanced head and neck cancer. Head & Neck 41:S1, pages 46-56.
Crossref
Alina Schneider, Ingo H. Gorr, Vincent Larraillet, Timo Frensing & Oliver Popp. (2019) Reduction of IL‐2 fragmentation during manufacturing of a novel immunocytokine by DoE process optimization. Biotechnology and Bioengineering 116:10, pages 2503-2513.
Crossref
Diana Darowski, Christian Jost, Kay Stubenrauch, Uwe Wessels, Jörg Benz, Andreas Ehler, Anne Freimoser-Grundschober, Peter Brünker, Ekkehard Mössner, Pablo Umaña, Sebastian Kobold & Christian Klein. (2019) P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Engineering, Design and Selection.
Crossref
Patrizia Murer & Dario Neri. (2019) Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. New Biotechnology 52, pages 42-53.
Crossref
Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo Antonio Ascierto, Stefano Cascinu, Jürgen C. Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer, Uwe Trefzer, Giuliano Elia, Dario Neri & Claus Garbe. (2019) A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy 68:9, pages 1547-1559.
Crossref
R. Lázaro-Gorines, J. Ruiz-de-la-Herrán, R. Navarro, L. Sanz, L. Álvarez-Vallina, A. Martínez-del-Pozo, J. G. Gavilanes & J. Lacadena. (2019) A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts. Scientific Reports 9:1.
Crossref
Jan P. Bogen, Steffen C. Hinz, Julius Grzeschik, Aileen Ebenig, Simon Krah, Stefan Zielonka & Harald Kolmar. (2019) Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma. Frontiers in Immunology 10.
Crossref
Jorick J. Bruins, Criss van de Wouw, Koen Wagner, Lina Bartels, Bauke Albada & Floris L. van Delft. (2019) Highly Efficient Mono-Functionalization of Knob-in-Hole Antibodies with Strain-Promoted Click Chemistry. ACS Omega 4:7, pages 11801-11807.
Crossref
Zinan Zhang, Florian Gothe, Perrine Pennamen, John R. James, David McDonald, Carlos P. Mata, Yorgo Modis, Anas M. Alazami, Meghan Acres, Wolfram Haller, Claire Bowen, Rainer Döffinger, Jan Sinclair, Shannon Brothers, Yu Zhang, Helen F. Matthews, Sophie Naudion, Fanny Pelluard, Huda Alajlan, Yasuhiro Yamazaki, Luigi D. Notarangelo, James E. Thaventhiran, Karin R. Engelhardt, Hamoud Al-Mousa, Sophie Hambleton, Caroline Rooryck, Kenneth G.C. Smith & Michael J. Lenardo. (2019) Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance. Journal of Experimental Medicine 216:6, pages 1311-1327.
Crossref
Barbara Bassani, Denisa Baci, Matteo Gallazzi, Alessandro Poggi, Antonino Bruno & Lorenzo Mortara. (2019) Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects. Cancers 11:4, pages 461.
Crossref
Cornelia Hutmacher, Nicolás Gonzalo Núñez, Anna Rita Liuzzi, Burkhard Becher & Dario Neri. (2019) Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells. Cancer Immunology Research 7:4, pages 572-583.
Crossref
Pamela Caudana, Nicolas Gonzalo Núñez, Philippe De La Rochere, Anaïs Pinto, Jordan Denizeau, Ruby Alonso, Leticia Laura Niborski, Olivier Lantz, Christine Sedlik & Eliane Piaggio. (2019) IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation. Cancer Immunology Research 7:3, pages 443-457.
Crossref
Jürgen Scheller, Erika Engelowski, Jens M. Moll & Doreen M. Floss. (2019) Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends in Immunology 40:3, pages 258-272.
Crossref
Anthony Tang & Fiona Harding. (2019) The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer. Cytokine: X 1:1, pages 100001.
Crossref
Gaurav Nayyar, Yaya Chu & Mitchell S. Cairo. (2019) Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. Frontiers in Oncology 9.
Crossref
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, Jenny Valladeau-Guilemond, Sandrine Valsesia-Wittmann, Sebastian Amigorena, Christophe Caux & Stéphane Depil. (2019) Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology 10.
Crossref
Lina Bartels, Hidde L. Ploegh, Hergen Spits & Koen Wagner. (2019) Preparation of bispecific antibody-protein adducts by site-specific chemo-enzymatic conjugation. Methods 154, pages 93-101.
Crossref
Cornelia Hutmacher & Dario Neri. (2019) Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Advanced Drug Delivery Reviews 141, pages 67-91.
Crossref
Gertrudis Rojas, Tania Carmenate, Julio Felipe Santo-Tomás, Pedro A. Valiente, Marlies Becker, Annia Pérez-Riverón, Yaima Tundidor, Yaquelín Ortiz, Jorge Fernandez de Cossio-Diaz, Luis Graça, Stefan Dübel & Kalet León. (2019) Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. Scientific Reports 9:1.
Crossref
Pedro Berraondo, Miguel F. Sanmamed, María C Ochoa, Iñaki Etxeberria, Maria A. Aznar, José Luis Pérez-Gracia, María E. Rodríguez-Ruiz, Mariano Ponz-Sarvise, Eduardo Castañón & Ignacio Melero. (2018) Cytokines in clinical cancer immunotherapy. British Journal of Cancer 120:1, pages 6-15.
Crossref
Adam Ajina & John Maher. 2019. Cancer Immunotherapy. Cancer Immunotherapy 217 292 .
Aras Toker & Pamela S. Ohashi. 2019. 193 261 .
Jean-Charles Ryff & Sidney Pestka. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 619 643 .
Lorenzo Mortara, Enrica Balza, Antonino Bruno, Alessandro Poggi, Paola Orecchia & Barbara Carnemolla. (2018) Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Frontiers in Immunology 9.
Crossref
Noritaka Hashii & Akiko Ishii-Watabe. (2018) Site-specific <i>O</i>-Glycosylation Analysis of Therapeutic Fc-fusion Protein by Mass Spectrometry質量分析によるFc融合タンパク質医薬品の<i>O</i>-結合型糖鎖部位特異的解析. YAKUGAKU ZASSHI 138:12, pages 1483-1494.
Crossref
Miguel F. Sanmamed & Lieping Chen. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:2, pages 313-326.
Crossref
Roberto De Luca & Dario Neri. (2018) Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains. Cancer Immunology, Immunotherapy 67:9, pages 1381-1391.
Crossref
Samuele Cazzamalli, Barbara Ziffels, Fontaine Widmayer, Patrizia Murer, Giovanni Pellegrini, Francesca Pretto, Sarah Wulhfard & Dario Neri. (2018) Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2. Clinical Cancer Research 24:15, pages 3656-3667.
Crossref
Benjamin Ribba, Christophe Boetsch, Tapan Nayak, Hans Peter Grimm, Jehad Charo, Stefan Evers, Christian Klein, Jean Tessier, Jean Eric Charoin, Alex Phipps, Pavel Pisa & Volker Teichgräber. (2018) Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. Clinical Cancer Research 24:14, pages 3325-3333.
Crossref
Emilie M.J. van Brummelen, Marc C. Huisman, Linda J. de Wit-van der Veen, Tapan K. Nayak, Marcel P.M. Stokkel, Emma R. Mulder, Otto S. Hoekstra, Danielle J. Vugts, Guus A.M.S. Van Dongen, Henk M. Verheul, Stefan Evers, Jean J. L. Tessier, Jose Saro, Jan H.M. Schellens & C. Willemien Menke-van der Houven van Oordt. (2018) 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. Oncotarget 9:37, pages 24737-24749.
Crossref
Weijun Wei, Dawei Jiang, Emily B. Ehlerding, Quanyong Luo & Weibo Cai. (2018) Noninvasive PET Imaging of T cells. Trends in Cancer 4:5, pages 359-373.
Crossref
Naroa Serna, Laura Sánchez-García, Ugutz Unzueta, Raquel Díaz, Esther Vázquez, Ramón Mangues & Antonio Villaverde. (2018) Protein-Based Therapeutic Killing for Cancer Therapies. Trends in Biotechnology 36:3, pages 318-335.
Crossref
Hans D. Menssen, Ulf Harnack, Ulrike Erben, Dario Neri, Burkhard Hirsch & Horst Dürkop. (2018) Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model. Journal of Cancer Research and Clinical Oncology 144:3, pages 499-507.
Crossref
Siddesh V. Hartimath, Valeria Manuelli, Rolf Zijlma, Alberto Signore, Tapan K. Nayak, Anne Freimoser-Grundschober, Christian Klein, Rudi A.J.O. Dierckx & Erik F.J. de Vries. (2018) Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. Oncotarget 9:6, pages 7162-7174.
Crossref
Christian Fercher, Sahar Keshvari, Michael A McGuckin & Ross T Barnard. (2017) Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins. Experimental Biology and Medicine 243:2, pages 166-183.
Crossref
Kalet León, Karina García-Martínez, Tania Carmenate & Gertrudis Rojas. (2018) Combining computational and experimental biology to develop therapeutically valuable IL2 muteins. Seminars in Oncology 45:1-2, pages 95-104.
Crossref
William R. Strohl. (2017) Current progress in innovative engineered antibodies. Protein & Cell 9:1, pages 86-120.
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
A. A. Lugovskoy. (2017) Engineering Antibodies as Drugs: Principles and Practice. Molecular Biology 51:6, pages 772-781.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.